Immunosyn Corporation, Inc. (IMYN.OB) Working on a Fast Track
The world of new biotech medications is one of approvals and big money. Put the two together and a large reward may be at the end of the rainbow. A misstep, anywhere along the yellow brick road, and the wicked witch may be waiting. Immunosyn Corporation, Inc., a biotechnology company oriented toward developing new products directed at auto immune disorders, is currently proceeding with trial start-up of its world rights granted SF-1019 product. The SF-1019 product is designed to address issues such as: diabetes, diabetic neuropathy, multiple sclerosis and other numerous neurological disorders. In more traditional drug trial schedules, the…